About Javeri
Product & Services
Equity
Derivatives
Mutual Funds
IPO
Corporate Info
Research
Contact Us
Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME
>
CORPORATE INFO
>
COMPANY NEWS
Company
News
Biocon Ltd.
Change Company
BSE Code
532523
ISIN Demat
INE376G01013
Book Value
119.86
NSE Code
BIOCON
Dividend Yield %
0.14
Market Cap
475424.27
P/E
78.03
EPS
4.56
Face Value
5
1 Week
1 Month
3 Months
6 Months
1 Year
30-Jun-2025
Biocon’s arm expands insulin access in Malaysia
30-Jun-2025
Biocon informs about press release
27-Jun-2025
Biocon’s arm receives NOC from Health Canada for ...
27-Jun-2025
Biocon informs about press release
27-Jun-2025
Biocon moves up as its arm receives NOC from Heal...
26-Jun-2025
Qualified Institutions Placement - Approval And ...
26-Jun-2025
Substantial Acquisition of Shares
26-Jun-2025
Biocon informs about communication to shareholder...
24-Jun-2025
Biocon’s arm partners with National Cancer Societ...
24-Jun-2025
Biocon informs about press release
18-Jun-2025
Biocon informs about credit rating
17-Jun-2025
Biocon to raise up to Rs 4,500 crore via QIP
16-Jun-2025
Biocon informs about outcome of board meeting
03-Jun-2025
Biocon gets approval for diabetes drug Liraglutid...
03-Jun-2025
Biocon rises on getting approval for diabetes dru...
Page
1
of
5
Prev
||
Next
Disclaimer
|
Privacy Policy
| Grievance |
FAQ
|
Sitemap |
Client Registration |
Useful Links
|
Anti Money Laundering
|
Inactive Client Policy
|
Scores
Vernacular Kyc
|
Advisory For Investors
|
Investor Adviser
|
Filing complaints on SCORES - Easy & quick
|
Policy on PMLA
Publishing of investor charter information
|
Annexure A – Investor charter of brokers
|
Annexure A – Investor charter of DP
|
Annexure B –Linked content for information to charter for DP
|
Annexure B & C (investor complaint data) broker & DP
Investor Charter & Complaints
|
Advisory-KYC Compliance
|
E-Voting NSE
|
E-Voting BSE
|
Details of Client Bank Accounts
|
Risk Disclosure
|
NSE FO Risk disclosure
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by
Accord Fintech Pvt. Ltd.
CLOSE
X
RISK DISCLOSURES ON DERIVATIVES
9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source:
Click Here.